Anti-IL-18 (Clone 125-2H) (Human) mAb (Monoclonal Antibody)
Interleukin 18 (IL-18) is a 18 kDa cytokine which identified as a costimulatory factor for production of interferon-γ (IFN-γ) in response to toxic shock and shares functional similarities with IL-12. IL-18 is synthesized as a precursor 24 kDa molecule without a signal peptide and must be cleaved to produce an active molecule. IL-1 converting enzyme (ICE, Caspase-1) cleaves pro-IL-18 at aspartic acid in the P1 position, producing the mature, bioactive peptide that is readily released from the cells. It is reported that IL-18 is produced from Kupffer cells, activated macrophages, keratinocytes, intestinal epithelial cells, osteoblasts, adrenal cortex cells and murine diencephalon. IFN-γ is produced by activated T or NK cells and plays critical roles in the defense against microbial pathogens. IFN-γ activates macrophages, enhances NK activity and B cell maturation, proliferation and Ig secretion, induces MHC class I and II antigens, and inhibits osteoclast activation. IL-18 acts on T helper type-1 (Th1) T cells and in combination with IL-12 strongly induces them to produce IFN-γ. Pleiotropic effects of IL-18 has also been reported, such as, enhancement production of IFN-γ and GM-CSF in peripheral blood mononuclear cells, production of Th1 cytokines, IL-2, GM-CSF and IFN-γ in T cells, enhancement of Fas ligand expression by Th1 cells.
Monoclonal antibody for targeting IL-18 for ELISA, IC, IPP, NT.
Target | IL-18 |
---|---|
Product Type | Antibody |
Application | ELISA, IP, NT |
Clonality | Monoclonal |
Conjugate | Unlabeled |
Isotype | IgG1 |
Immunogen | Recombinant human IL-18 |
Host Species | Mouse |
Species Reactivity | Human |
Formulation | 100 µg IgG in 100 µl volume of PBS containing 50% glycerol, pH 7.2. No preservative is contained. |
Research Area | Immunology |
Storage Temperature | -20°C |
Protocols | ELISA, IP, NT |
Clone Number | 125-2H |
Concentration | 1 mg/mL |
Regulatory Statement | For Research Use Only. Not for use in diagnostic procedures. |